Introduction
Despite of the widespread availability of antibiotics, urinary tract infections (UTIs) remain the second most common infectious presentation in humans, both in the community and the hospital settings. It affects approximately 150 million people worldwide annually which results in more than 6 billion US dollars loss to the global economy. 1 As many as 80% of UTIs are caused by Escherichia coli. Antimicrobial resistance in uropathogenic E. coli is of major concern worldwide due to its increasing resistance to several commonly prescribed antibiotics. 2 Presently, production of extended spectrum β-lactamase (ESBL) and AmpC β-lactamase limits the use of β-lactam antibiotics against the infections caused by E. coli.
3
ESBLs are enzymes that have the ability to hydrolyze and cause resistance to various types of newer β-lactam antibiotics, including the expanded-spectrum cephalosporins (e.g., cefotaxime, ceftriaxone, ceftazidime) and monobactams (e.g., aztreonam), but not the cephamycins (e.g., cefoxitin and cefotetan) and carbapenems (e.g., imipenem, meropenem, and ertapenem 
